Abstract:Due to the COVID‐19 pandemic, a series of sequelae, such as fatigue, tachypnea and ageusia, appeared in long COVID patients, but the pathological basis was still uncertain. The targeted radiopharmaceuticals were of potentials to systemically and dynamically trace the pathological changes. For the key ACE2 protein in the virus‐host interaction, 68Ga‐cyc‐DX600 was developed on the basis of DX600 as a PET tracer of ACE2 fluctuation, and maintained the ability in differentiating ACE and ACE2. In the temporary infection model inhaled with the radio‐traceable pseudovirus in the upper respiratory of male humanized ACE2 (hACE2) mice, organ‐specific ACE2 dysfunction in acute period and the following ACE2 recovery in a relatively long period were visualized and quantified by ACE2 PET, revealing a complex pattern of virus concentration‐dependent degree and time period‐dependent tendency of ACE2 recovery, mainly a sudden decrease of apparent ACE2 in heart, liver, kidneys, lungs and so on, but liver was of a quick functional compensation on ACE2 expression after a temporary decrease. ACE2 expression of most organs has recovered to a normal level at 15 days P.I., with brain and genitals still of a decreased SUVACE2, meanwhile, kidneys were of an increased SUVACE2. These findings on ACE2 PET were further verified by western blot. When compared with high‐resolution computed tomography on structural changes and FDG PET on glycometabolism, ACE2 PET was of the superiority on earlier diagnostic window during infection and more comprehensive understanding of functional dysfunction post infection. In the respective ACE2 PET/CT and ACE2 PET/MR scans of a volunteer, the repeatability of SUVACE2 and the ACE2 specificity were further confirmed. In conclusion, 68Ga‐cyc‐DX600 was developed as an ACE2‐specific tracer, and the corresponding ACE2 PET revealed the dynamic patterns of functional ACE2 recovery and provided a reference and approach to explore the ACE2‐related pathological basis of sequelae in long COVID. This article is protected by copyright. All rights reserved.

Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS‐CoV‐2

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy.

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy

Single-cell RNA expression profiling shows that ACE2, the putative receptor of COVID-2019, has significant expression in nasal and mouth tissue, and is co-expressed with TMPRSS2 and not co-expressed with SLC6A19 in the tissues

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudocorona Virus.

ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudo Corona Virus

Preclinical Evaluation and Pilot Clinical Study of Al18F-DX600-BCH for non-invasive PET Mapping of Angiotensin Converting Enzyme 2 in Mammal

Preclinical Evaluation and Pilot Clinical Study of 18F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2

Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2

Transcriptomics Curation of SARS-CoV-2 Related Host Genes in Mice With COVID-19 Comorbidity: A Pilot Study

Evaluation of Angiotensin-Converting Enzyme 2 Expression In Vivo with Novel 68Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain

A Comprehensive Investigation of the Mrna and Protein Level of ACE2, the Putative Receptor of SARS-CoV-2, in Human Tissues and Blood Cells.

Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2

Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2

A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19

Positron emission tomography in the COVID-19 pandemic era

Noninvasive Mapping of Angiotensin Converting Enzyme-2 in Pigeons Using Micro Positron Emission Tomography.

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs